Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody [2]

Acta Dermato-Venereologica

Volumn 81, Issue 3, 2001, Pages 207-208

  Soda, R ^a   Costanzo, A ^a   Cantonetti, M ^a   Orlandi, A ^a   Bianchi, L ^a   Chimenti, S ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; MONOCLONAL ANTIBODY; RITUXIMAB;

ADULT; B CELL LYMPHOMA; CANCER IMMUNOTHERAPY; CASE REPORT; HUMAN; HUMAN TISSUE; IMMUNOHISTOLOGY; LETTER; MALE; PRIORITY JOURNAL; SIDE EFFECT; SKIN BIOPSY; SKIN LYMPHOMA; SKIN TUMOR; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, B-CELL; MALE; SKIN NEOPLASMS;

EID: 0034874849     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.1080/000155501750376339     Document Type: Letter

References (11)

1. EORTC classification for primary cutaneous lymphomas: A proposal from the cutaneous lymphoma study group of the European Organization for Research and Treatment of Cancer
2. Use of recombinant interferon α-2a in the treatment of cutaneous lymphoma of T and B lineage
3. Treatment of multifocal primary cutaneous B.-cell lymphoma: A clinical follow-up study of 29 patients
4. Current treatment of follicular low-grade lymphomas
5. Rituximab in cutaneous B cell lymphoma: A report of two cases
6. Preclinical and phase I and II trials of rituximab
7. Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma
8. Idec-C2B8 (rituximab) anti CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
9. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four dose treatment program
10. Therapy of B-cell lymphoma with anti CD20 antibodies can result in the loss of CD20 antigen expression
11. Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy